Unlike single-pathway therapies, Tirzepatide is a dual-action medication that activates both GLP-1 and GIP receptors simultaneously addressing appetite, satiety, insulin response, and fat metabolism
PMC (PubMed Central)
Such a clean, isolated dataset for cagrilintide monotherapy is not prominent in the peer-reviewed literature, and this gap is itself an important finding
[121] [123] Malabsorption [edit] Individuals with pernicious anemia do not have the ability to produce intrinsic factor
For example, for claims with dates of service between October 1, 2026, through December 31, 2026, covered entities that choose to submit data elements from Part D 340B claims would submit the data to the 340B repository no later than March 31, 2027